Cory Kasimov
Great. Were down to one minute left. I want to work in this one question in the portal that asks about the progress youre making with allergy programs against bird, peanut and cat allergies. Can you summarize super quick how those are going?
George Yancopoulos
Well, once again, those are also first-in-class programs that were very excited about. Weve designed -- the reason you get allergies as your body makes the bad IgE, E for evil antibodies, against all these allergens. We are simply making IgG versions of these antibodies that essentially block the evil IgE antibodies and prevent allergies.
Our Phase II data in these programs are really extraordinary. They really are shutting down allergy. And I think that the only challenge is that there are rather complicated Phase III programs that need to be designed in the real-world setting in patients that have multiple allergies, where it may be challenging to show the effects on individual allergies.
But the Phase II studies that are studying specifically allergen-induced responses in these patients have been exquisitely blocked and attacked by our anti-allergen IgG antibodies in both the cat and the bird setting. So we think these are very exciting programs. They are somewhat challenging to design in the real-world setting in patients with multi-allergies, the Phase III programs.
